Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
doi:10.1016/j.cmet.2015.06.003
AnaptysBio is developing its own wholly owned PD-1 agonist candidate for rheumatoid arthritis, rosnilimab, with data expected in Q1 2025
Protein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer
While complications are rare, individuals with very sensitive skin, a history of keloid scarring, or certain skin conditions may face a higher risk for adverse effects
US$ 28.37
US$ 28.92
US$ 27.73
US$ 25.04
